Similar articles

• Editorial comment on: new treatment approaches for prostate cancer based on peptide analogues.

  McLeod DG. McLeod DG. Eur Urol. 2008 May;53(5):898-9. doi: 10.1016/j.eururo.2007.12.022. Epub 2007 Dec 26. Eur Urol. 2008. PMID: 18201816 No abstract available.
• New treatment approaches for prostate cancer based on peptide analogues.

  Stangelberger A, Schally AV, Djavan B. Stangelberger A, et al. Eur Urol. 2008 May;53(5):890-900. doi: 10.1016/j.eururo.2007.12.021. Epub 2007 Dec 26. Eur Urol. 2008. PMID: 18201818 Review.
• Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.

  Koutsilieris M, Dimopoulos T, Milathianakis C, Bogdanos J, Karamanolakis D, Pissimissis N, Halapas A, Lembessis P, Papaioannou A, Sourla A. Koutsilieris M, et al. BJU Int. 2007 Jul;100 Suppl 2:60-2. doi: 10.1111/j.1464-410X.2007.06958.x. BJU Int. 2007. PMID: 17594363 Review. No abstract available.
• Combined androgen blockade revisited: emerging options for the treatment of castration-resistant prostate cancer.

  Simmons MN, Klein EA. Simmons MN, et al. Urology. 2009 Apr;73(4):697-705. doi: 10.1016/j.urology.2008.09.040. Epub 2009 Jan 30. Urology. 2009. PMID: 19185908 Review. No abstract available.
• Editorial comment.

  Roach M 3rd. Roach M 3rd. J Urol. 2010 Feb;183(2):551. doi: 10.1016/j.juro.2009.10.107. Epub 2009 Dec 14. J Urol. 2010. PMID: 20006855 No abstract available.